Zobrazeno 1 - 10
of 153
pro vyhledávání: ''
Autor:
Hervé Dombret, Simon Durrant, Christopher Larry Bacon, Qui Tran, Max S. Topp, Andre C. Schuh, Zachary Zimmerman, Hagop M. Kantarjian, Andrew H. Wei
Publikováno v:
Leukemialymphoma. 60(9)
Outcomes for adults with relapsed/refractory acute lymphoblastic leukemia (ALL) are poor with chemotherapy, particularly in later salvage. The TOWER study examined survival, remission, bridge to allogeneic hematopoietic stem cell transplantation (HSC
Autor:
Arinobu Tojo, Masamichi Isobe, Seiko Kato, Takaaki Konuma, Mai Mizusawa, Kazuaki Yokoyama, Maki Oiwa-Monna, Satoshi Takahashi
Publikováno v:
Leukemialymphoma. 60(9)
Genetic mutation is one of the most powerful prognostic factors for adult patients with acute myeloid leukemia (AML). The FMS-like tyrosine kinase 3 (FLT3) gene mutations, including internal tandem...
Publikováno v:
Leukemialymphoma. 60(5)
Chronic lymphocytic leukemia (CLL) constitutes the largest percentage of adult leukemia cases in Western countries. Classically, fludarabine (Flu) is an effective drug used as a first-line therapy for CLL; however, Flu resistance limits its clinical
Publikováno v:
Leukemialymphoma. 60(5)
Pegylated asparaginase (PEG-Asp), a key component in the treatment of acute lymphoblastic leukemia (ALL), is associated with coagulopathy and an increased risk of venous thromboembolism (VTE). PEG-Asp also lowers antithrombin (AT) levels. Between Apr
Autor:
Tomas Cudrnak, Manuel Saenz-de-Viteri
Publikováno v:
Leukemialymphoma. 60(3)
Ocular side effects associated with cytotoxic chemotherapy are rarely severe or dose limiting but serious toxicity has been associated with molecularly targeted cancer therapies, particularly tyros...
Autor:
Andrea Janíková, Jan Walewski, Thomas Herz, Babett Krauss, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, Andrzej Hellmann, Stefan W. Henning, Agnieszka Warszewska, A. Mais, Astrid S. Ammendola
Publikováno v:
Leukemialymphoma. 60(3)
This open-label, single-arm phase II study examined efficacy, safety, pharmacokinetics, and biomarkers of histone deacetylase (HDAC) inhibitor resminostat in patients with relapsed or refractory Hodgkin lymphoma. Thirty-seven heavily pretreated patie
Publikováno v:
Leukemialymphoma. 60(1)
Clinical prognostic scores have been integral to risk assessment and therapeutic decision making in patients with hematological malignancies. The Sokal, Hasford and European Treatment and Outcome S...
Autor:
Vincent Parinet, Dorothée Selimoglu-Buet, Nicolas Noel, Nathalie Droin, Marc Humbert, Nolwenn Lucas, Olivier Lambotte, Eric Solary, Véronique Saada
Publikováno v:
Leukemialymphoma. 58(12)
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder that associates dysplastic and proliferative features. Tissue inflammatory disorders occur in a fraction of CMML patients during the course of their disease. Here, we describe
Autor:
Thibaut Challan Belval, Blandine Denis, Jean Marc Zini, Marion Malphettes, Marguerite Vignon, Alexandre Alanio, Marine Baron
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2017, 58 (12), pp.2981-2982. ⟨10.1080/10428194.2017.1320710⟩
Leukemia & lymphoma, 2017, 58 (12), pp.2981-2982. ⟨10.1080/10428194.2017.1320710⟩
Leukemia & lymphoma, Taylor & Francis, 2017, 58 (12), pp.2981-2982. ⟨10.1080/10428194.2017.1320710⟩
Leukemia & lymphoma, 2017, 58 (12), pp.2981-2982. ⟨10.1080/10428194.2017.1320710⟩
International audience; Letters to the editor
Autor:
Soo-Hyun Kim, Kyung-Mi Kee, Dong-Wook Kim, Hee-Jeong Hwang, Hye-Young Song, Mi-Young Lee, Hae-Lyun Yoo, Ki-Hoon Kang, Sung-Eun Lee, Soo Young Choi, Eun-Jung Jang
Publikováno v:
Leukemialymphoma. 59(1)
We conducted this study to identify the factors for predicting poor outcomes in chronic myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR). Of the 413 newly diagnosed, chronic phase, chronic myeloid leukemia pati